PetVivo closes Series B Convertible Preferred Stock offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2025
0mins
Should l Buy ?
Equity Financing Agreement: PetVivo Holdings has entered a Subscription Agreement for $5 million in equity financing, receiving an initial $600,000 with the option for an additional $4.4 million expected within 60 days.
Product Commercialization: The funds will support the commercialization of PetVivo's products, including SPRYNG with OsteoCushion Technology, which is designed to manage joint pain in animals by restoring proper joint mechanics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
